Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of daratumumab plus DCEP in multiple myeloma patients with plasmacytoma lacking complete remission after bortezomib-based induction
KCT0003345Phase 2Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), plasmacytoma, sponsored by Janssen Pharmaceutical. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)plasmacytoma
Beyond the preview
Go deeper on KCT0003345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003345.